Comparison of the Antibody Responses Following Vaccination with AstraZeneca and Sinopharm.

IF 1.1 4区医学 Q4 IMMUNOLOGY

Iranian Journal of Immunology Pub Date : 2022-09-01 DOI:10.22034/iji.2022.94298.2300

Enayat Anvari, Atefe Ghamar Talepoor, Mahsa Eshkevar Vakili, Narges Karimi, MohammadReza Ataollahi, Gelareh Najafi, Dieter Kabalitz, Iraj Ahmadi, Kurosh Kalantar

{"title":"Comparison of the Antibody Responses Following Vaccination with AstraZeneca and Sinopharm.","authors":"Enayat Anvari, Atefe Ghamar Talepoor, Mahsa Eshkevar Vakili, Narges Karimi, MohammadReza Ataollahi, Gelareh Najafi, Dieter Kabalitz, Iraj Ahmadi, Kurosh Kalantar","doi":"10.22034/iji.2022.94298.2300","DOIUrl":null,"url":null,"abstract":"Background: Vaccines are the most effective way to prevent Coronavirus 2 severe acute respiratory syndrome (SARS-CoV-2).Objectives: To compare the antibody response of healthy individuals vaccinated with either the AstraZeneca (ChAdOx1 nCoV-19) or the Sinopharm (BBIBP-CorV) vaccine, in those who had no prior infection with SARS-CoV-2.Methods: Thirty seven participants were included, of which 17 were administered the AstraZeneca (ChAdOx1 nCoV-19) vaccine, while 20 were given the Sinopharm (BBIBP-CorV) vaccine. SARS-CoV-2 neutralizing antibody and anti-receptor-binding domain (RBD) IgG levels were checked 4 weeks after giving the first and the second dose of either vaccine using the enzyme-linked immunosorbent assay (ELISA) technique.Results: The AstraZeneca (ChAdOx1 nCoV-19) vaccine exhibited a higher levels of anti-(RBD) IgG compared with the Sinopharm (BBIBP-CorV) in both the first (14.51 μg/ml vs. 1.160 μg/ml) and the second (46.68 μg/ml vs. 11.43 μg/ml) doses. About neutralizing Abs, the titer of the antibody was higher in the AstraZeneca (ChAdOx1 nCoV-19) recipients than in the Sinopharm (BBIBP-CorV) subjects after the first (7.77 μg/ml vs. 1.79 μg/ml, p < 0.0001) and the second dose (10. 36 μg/ml vs. 4.88 μg/ml, p < 0.0001).Conclusions: Recipients vaccinated with two doses of the AstraZeneca (ChAdOx1 nCoV-19) had superior quantitative antibody levels than Sinopharm (BBIBP-CorV)-vaccinated subjects. These data suggest that a booster dose may be needed for the Sinopharm (BBIBP-CorV) recipients, to control the COVID-19 pandemic.","PeriodicalId":54921,"journal":{"name":"Iranian Journal of Immunology","volume":"19 3","pages":"321-329"},"PeriodicalIF":1.1000,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Iranian Journal of Immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.22034/iji.2022.94298.2300","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 2

Abstract

Background: Vaccines are the most effective way to prevent Coronavirus 2 severe acute respiratory syndrome (SARS-CoV-2).

Objectives: To compare the antibody response of healthy individuals vaccinated with either the AstraZeneca (ChAdOx1 nCoV-19) or the Sinopharm (BBIBP-CorV) vaccine, in those who had no prior infection with SARS-CoV-2.

Methods: Thirty seven participants were included, of which 17 were administered the AstraZeneca (ChAdOx1 nCoV-19) vaccine, while 20 were given the Sinopharm (BBIBP-CorV) vaccine. SARS-CoV-2 neutralizing antibody and anti-receptor-binding domain (RBD) IgG levels were checked 4 weeks after giving the first and the second dose of either vaccine using the enzyme-linked immunosorbent assay (ELISA) technique.

Results: The AstraZeneca (ChAdOx1 nCoV-19) vaccine exhibited a higher levels of anti-(RBD) IgG compared with the Sinopharm (BBIBP-CorV) in both the first (14.51 μg/ml vs. 1.160 μg/ml) and the second (46.68 μg/ml vs. 11.43 μg/ml) doses. About neutralizing Abs, the titer of the antibody was higher in the AstraZeneca (ChAdOx1 nCoV-19) recipients than in the Sinopharm (BBIBP-CorV) subjects after the first (7.77 μg/ml vs. 1.79 μg/ml, p < 0.0001) and the second dose (10. 36 μg/ml vs. 4.88 μg/ml, p < 0.0001).

Conclusions: Recipients vaccinated with two doses of the AstraZeneca (ChAdOx1 nCoV-19) had superior quantitative antibody levels than Sinopharm (BBIBP-CorV)-vaccinated subjects. These data suggest that a booster dose may be needed for the Sinopharm (BBIBP-CorV) recipients, to control the COVID-19 pandemic.

查看原文本刊更多论文

阿斯利康与国药疫苗接种后抗体反应的比较。

背景:疫苗是预防冠状病毒2型严重急性呼吸综合征(SARS-CoV-2)最有效的方法。目的:比较既往未感染SARS-CoV-2的健康人接种阿斯利康(ChAdOx1 nCoV-19)或国药(BBIBP-CorV)疫苗后的抗体反应。方法:纳入37例受试者，其中阿斯利康(ChAdOx1) nCoV-19疫苗17例，国药(BBIBP-CorV)疫苗20例。采用酶联免疫吸附试验(ELISA)技术，在接种第一剂和第二剂疫苗4周后检测SARS-CoV-2中和抗体和抗受体结合域(RBD) IgG水平。结果:阿斯利康(ChAdOx1 nCoV-19)疫苗第一剂量(14.51 μg/ml vs. 1.160 μg/ml)和第二剂量(46.68 μg/ml vs. 11.43 μg/ml)的抗(RBD) IgG水平均高于国药(BBIBP-CorV)。在中和抗体方面，阿斯利康(ChAdOx1 nCoV-19)和国药(BBIBP-CorV)第一次和第二次接种后的抗体滴度分别为7.77 μg/ml和1.79 μg/ml, p < 0.0001)高于国药(BBIBP-CorV)。36 μg/ml vs. 4.88 μg/ml, p < 0.0001)。结论:两剂阿斯利康(ChAdOx1 - nCoV-19)疫苗接种者的定量抗体水平高于国药(BBIBP-CorV)疫苗接种者。这些数据表明，为了控制COVID-19大流行，可能需要对国药控股(BBIBP-CorV)接种者进行加强剂量。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Iranian Journal of Immunology Medicine-Immunology and Allergy

CiteScore

1.60

自引率

0.00%

发文量

审稿时长

12 weeks

期刊介绍： The Iranian Journal of Immunology (I.J.I) is an internationally disseminated peer-reviewed publication and publishes a broad range of experimental and theoretical studies concerned with all aspects of immunology.